More on MDMA
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.00 |
|
|||
| Open | $0.00 | ||||
| 52 Wk High | $0.00 | ||||
| 52 Wk Low | $0.00 | ||||
| Day High | $0.00 | ||||
| Day Low | $0.00 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 0 | ||||
- PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100
- Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
- PharmAla Biotech forms joint venture for APA-01 drug development
- PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
- PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
- PharmAla Issues Q2 Financial Statements and Grants Options
- Cortexa Advances Commercialisation of MDMA Supply in Australia
- PharmAla signs supply deal with Nautilus Sanctuary for phase 2 MDMA trial
- PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Resp
- PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia
Entities mentioned with MDMA
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Donald J. Trump | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
